SCHEMBL26984971

SCHEMBL26984971

Cc1c(Br)cncc1Nc1ccc(Cl)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 3/20 0.47
▸ EGFR P00533 3/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TRPM5 Q9NZQ8 1/20 0.39
▸ KDR P35968 5/20 0.38
▸ FLT1 P17948 4/20 0.38
▸ FGFR1 P11362 3/20 0.38
▸ EPHB2 P29323 1/20 0.38
▸ FLT4 P35916 1/20 0.38
▸ ERBB2 P04626 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746519 1.00 NUDT1 (0.47) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL26984979 0.85 NUDT1 (0.46) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL30746670 0.85 NUDT1 (0.46) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL26985001 0.82 NUDT1 (0.44) NUDT1EGFRKMT2ATRPM5KDR
SCHEMBL30746441 0.82 NUDT1 (0.44) NUDT1EGFRKMT2ATRPM5KDR
SCHEMBL30746657 0.81 NUDT1 (0.45) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL26985076 0.81 NUDT1 (0.45) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL31613386 0.80 NUDT1 (0.47) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL30746528 0.80 NUDT1 (0.47) NUDT1EGFRKMT2ANPC1RAB9A
SCHEMBL26985139 0.80 NUDT1 (0.47) NUDT1EGFRKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
EP-4551558-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS Nested Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 NUDT1 1810/4885EGFR 82/4885KMT2A 1855/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 NUDT1 2559/4885EGFR 145/4885KMT2A 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback